Allogene Therapeutics Announces Pricing of Initial Public Offering

FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Allogene Therapeutics Completes a $120 Million Private Financing

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

Allogene Therapeutics Announces Scientific Advisory Board

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

Allogene Therapeutics Announces Board of Directors

Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing

UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer

New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy

UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer

Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125

Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy

Hubble Contacts Launches Subscription Service in the UK

UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option